King's College London

Research portal

Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review

Research output: Contribution to journalReview articlepeer-review

Standard

Quality of life in patients with gastroenteropancreatic tumours : A systematic literature review. / Watson, Catherine; Tallentire, Craig William; Ramage, John K.; Srirajaskanthan, Rajaventhan; Leeuwenkamp, Oscar R.; Fountain, Donna.

In: World Journal of Gastroenterology, Vol. 26, No. 25, 07.07.2020, p. 3686-3711.

Research output: Contribution to journalReview articlepeer-review

Harvard

Watson, C, Tallentire, CW, Ramage, JK, Srirajaskanthan, R, Leeuwenkamp, OR & Fountain, D 2020, 'Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review', World Journal of Gastroenterology, vol. 26, no. 25, pp. 3686-3711. https://doi.org/10.3748/wjg.v26.i25.3686

APA

Watson, C., Tallentire, C. W., Ramage, J. K., Srirajaskanthan, R., Leeuwenkamp, O. R., & Fountain, D. (2020). Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review. World Journal of Gastroenterology, 26(25), 3686-3711. https://doi.org/10.3748/wjg.v26.i25.3686

Vancouver

Watson C, Tallentire CW, Ramage JK, Srirajaskanthan R, Leeuwenkamp OR, Fountain D. Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review. World Journal of Gastroenterology. 2020 Jul 7;26(25):3686-3711. https://doi.org/10.3748/wjg.v26.i25.3686

Author

Watson, Catherine ; Tallentire, Craig William ; Ramage, John K. ; Srirajaskanthan, Rajaventhan ; Leeuwenkamp, Oscar R. ; Fountain, Donna. / Quality of life in patients with gastroenteropancreatic tumours : A systematic literature review. In: World Journal of Gastroenterology. 2020 ; Vol. 26, No. 25. pp. 3686-3711.

Bibtex Download

@article{c191577b70f0466090abb0d688f0fef9,
title = "Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review",
abstract = "BACKGROUND Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are slow-growing cancers that arise from diffuse endocrine cells in the gastrointestinal tract (GINETs) or the pancreas (P-NETs). They are relatively uncommon, accounting for 2% of all gastrointestinal malignancies. The usual treatment options in advanced GEP-NET patients with metastatic disease include chemotherapy, biological therapies, and peptide receptor radionuclide therapy. Understanding the impact of treatment on GEP-NET patients is paramount given the nature of the disease. Health-related quality of life (HRQoL) is increasingly important as a concept reflecting the patients' perspective in conjunction with the disease presentation, severity and treatment. AIM To conduct a systematic literature review to identify literature reporting HRQoL data in patients with GEP-NETs between January 1985 and November 2019. METHODS The PRISMA guiding principles were applied. MEDLINE, Embase and the Cochrane library were searched. Data extracted from the publications included type of study, patient population data (mid-gut/hind-gut/GI-NET/P-NET), sample size, intervention/comparators, HRQoL instruments, average and data spread of overall and sub-scores, and follow-up time for data collection. RESULTS Forty-three publications met the inclusion criteria. The heterogeneous nature of the different study populations was evident; the percentage of female participants ranged between 30%-60%, whilst average age ranged from 53.8 to 67.0 years. Eight studies investigated GI-NET patients only, six studies focused exclusively on P-NET patients and the remaining studies involved both patient populations or did not report the location of the primary tumour. The most commonly used instrument was the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (n = 28) with consistent results across studies; the GI-NET-specific module Quality of Life Questionnaire-GINET21 was used in six of these studies. A number of randomised trials demonstrated no HRQoL changes between active treatment and placebo arms. The Phase III NETTER-1 study provides the best data available for advanced GEP-NET patients; it shows that peptide receptor radionuclide therapy can significantly improve GEP-NET patients' HRQoL. CONCLUSION HRQoL instruments offer a means to monitor patients' general disease condition, disease progression and their physical and mental well-being. Instruments including the commonly used European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 and GINET21 lack, however, validation and a defined minimal clinical important difference specifically for GINET and P-NET patients. ",
keywords = "Biological therapies, Chemotherapy, Gastroenteropancreatic neuroendocrine tumours, Health-related quality of life, Peptide receptor radionuclide therapy, Systematic literature review",
author = "Catherine Watson and Tallentire, {Craig William} and Ramage, {John K.} and Rajaventhan Srirajaskanthan and Leeuwenkamp, {Oscar R.} and Donna Fountain",
year = "2020",
month = jul,
day = "7",
doi = "10.3748/wjg.v26.i25.3686",
language = "English",
volume = "26",
pages = "3686--3711",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "25",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Quality of life in patients with gastroenteropancreatic tumours

T2 - A systematic literature review

AU - Watson, Catherine

AU - Tallentire, Craig William

AU - Ramage, John K.

AU - Srirajaskanthan, Rajaventhan

AU - Leeuwenkamp, Oscar R.

AU - Fountain, Donna

PY - 2020/7/7

Y1 - 2020/7/7

N2 - BACKGROUND Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are slow-growing cancers that arise from diffuse endocrine cells in the gastrointestinal tract (GINETs) or the pancreas (P-NETs). They are relatively uncommon, accounting for 2% of all gastrointestinal malignancies. The usual treatment options in advanced GEP-NET patients with metastatic disease include chemotherapy, biological therapies, and peptide receptor radionuclide therapy. Understanding the impact of treatment on GEP-NET patients is paramount given the nature of the disease. Health-related quality of life (HRQoL) is increasingly important as a concept reflecting the patients' perspective in conjunction with the disease presentation, severity and treatment. AIM To conduct a systematic literature review to identify literature reporting HRQoL data in patients with GEP-NETs between January 1985 and November 2019. METHODS The PRISMA guiding principles were applied. MEDLINE, Embase and the Cochrane library were searched. Data extracted from the publications included type of study, patient population data (mid-gut/hind-gut/GI-NET/P-NET), sample size, intervention/comparators, HRQoL instruments, average and data spread of overall and sub-scores, and follow-up time for data collection. RESULTS Forty-three publications met the inclusion criteria. The heterogeneous nature of the different study populations was evident; the percentage of female participants ranged between 30%-60%, whilst average age ranged from 53.8 to 67.0 years. Eight studies investigated GI-NET patients only, six studies focused exclusively on P-NET patients and the remaining studies involved both patient populations or did not report the location of the primary tumour. The most commonly used instrument was the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (n = 28) with consistent results across studies; the GI-NET-specific module Quality of Life Questionnaire-GINET21 was used in six of these studies. A number of randomised trials demonstrated no HRQoL changes between active treatment and placebo arms. The Phase III NETTER-1 study provides the best data available for advanced GEP-NET patients; it shows that peptide receptor radionuclide therapy can significantly improve GEP-NET patients' HRQoL. CONCLUSION HRQoL instruments offer a means to monitor patients' general disease condition, disease progression and their physical and mental well-being. Instruments including the commonly used European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 and GINET21 lack, however, validation and a defined minimal clinical important difference specifically for GINET and P-NET patients.

AB - BACKGROUND Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are slow-growing cancers that arise from diffuse endocrine cells in the gastrointestinal tract (GINETs) or the pancreas (P-NETs). They are relatively uncommon, accounting for 2% of all gastrointestinal malignancies. The usual treatment options in advanced GEP-NET patients with metastatic disease include chemotherapy, biological therapies, and peptide receptor radionuclide therapy. Understanding the impact of treatment on GEP-NET patients is paramount given the nature of the disease. Health-related quality of life (HRQoL) is increasingly important as a concept reflecting the patients' perspective in conjunction with the disease presentation, severity and treatment. AIM To conduct a systematic literature review to identify literature reporting HRQoL data in patients with GEP-NETs between January 1985 and November 2019. METHODS The PRISMA guiding principles were applied. MEDLINE, Embase and the Cochrane library were searched. Data extracted from the publications included type of study, patient population data (mid-gut/hind-gut/GI-NET/P-NET), sample size, intervention/comparators, HRQoL instruments, average and data spread of overall and sub-scores, and follow-up time for data collection. RESULTS Forty-three publications met the inclusion criteria. The heterogeneous nature of the different study populations was evident; the percentage of female participants ranged between 30%-60%, whilst average age ranged from 53.8 to 67.0 years. Eight studies investigated GI-NET patients only, six studies focused exclusively on P-NET patients and the remaining studies involved both patient populations or did not report the location of the primary tumour. The most commonly used instrument was the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (n = 28) with consistent results across studies; the GI-NET-specific module Quality of Life Questionnaire-GINET21 was used in six of these studies. A number of randomised trials demonstrated no HRQoL changes between active treatment and placebo arms. The Phase III NETTER-1 study provides the best data available for advanced GEP-NET patients; it shows that peptide receptor radionuclide therapy can significantly improve GEP-NET patients' HRQoL. CONCLUSION HRQoL instruments offer a means to monitor patients' general disease condition, disease progression and their physical and mental well-being. Instruments including the commonly used European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 and GINET21 lack, however, validation and a defined minimal clinical important difference specifically for GINET and P-NET patients.

KW - Biological therapies

KW - Chemotherapy

KW - Gastroenteropancreatic neuroendocrine tumours

KW - Health-related quality of life

KW - Peptide receptor radionuclide therapy

KW - Systematic literature review

UR - http://www.scopus.com/inward/record.url?scp=85088906892&partnerID=8YFLogxK

U2 - 10.3748/wjg.v26.i25.3686

DO - 10.3748/wjg.v26.i25.3686

M3 - Review article

C2 - 32742136

AN - SCOPUS:85088906892

VL - 26

SP - 3686

EP - 3711

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 25

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454